
Keywords: VVA; vulvovaginal atrophy; SERM; selective estrogen receptor modulator; NDA; new drug application; FDA; Food and Drug Administration; NSABP; National Surgical Adjuvant Breast & Bowel Project; STAR; Study of Tamoxifen and Raloxifene; ER; estrogen receptor;